Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 734-740

 

^a Clinical Trial Safety and Public Health   (France)

Author keywords

Direct acting antivirals; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; CLINICAL TRIAL; COMPASSIONATE USE; LIVER TUMOR; MULTICENTER STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COMPASSIONATE USE TRIALS; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84979669607     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.045     Document Type: Article

References (14)

1. [1] Alqahtani, S.A., Afdhal, N., Zeuzem, S., Gordon, S.C., Mangia, A., Kwo, P., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology 62 (2015), 25–30.
2. [2] Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Etzkorn, K., Rojter, S., et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology, 2016, 10.1002/hep.28467 [Epub ahead of print].
3. [3] Pol, S., Lucier, S., de Lédinghen, V., Zoulim, F., Dorival-Mouly, C., et al. Safety and efficacy of the combination Daclatasvir sofosbuvir in HCV genotype 1-mono-infected patients from the French Observational cohort ANRS CO22. J Hepatol, 62, 2015, S258.
4. [4] Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
5. [5] Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
6. [6] Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
7. [7] Buonfiglioli, F., Conti, F., Andreone, P., Crespi, C., Foschi, G., Lenzi, M., et al. Development of hepatocellular carcinoma in HCV cirrhosis patients treated with direct acting antivirals. J Hepatol, 64, 2016, LB506.
8. [8] Trinchet, J.C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
9. [9] Bruix, J., Sherman, M., Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
10. [10] Clavien, P.A., Lesurtel, M., Bossuyt, P.M., Gores, G.J., Langer, B., Perrier, A., Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13 (2012), e11–e22.
11. [11] Alanio, C., Nicoli, F., Sultanik, P., Flecken, T., Perot, B., Duffy, D., et al. Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients. Elife, 2015, 10.7554/eLife.07916 pii: e07916.
12. [12] Hengst, J., Schlaphoff, Verena, Deterding, K., Falk, C.S., Manns, M.P., Cornberg, M., Wedemeyer, H., DAA-induced HCV clearance does not restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Hepatol, 64, 2016, THU258.
13. [13] Meissner, E.G., Wu, D., Osinusi, A., Bon, D., Virtaneva, K., Sturdevant, D., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
14. [14] Clinical outcomes in HCV-infected patients treated with direct acting antivirals-18 month post-treatment follow-up in the French ANRS CO22 HEPATHER Cohort Study. ANRS/AFEF HEPATHER Study Group. J Hepatol, 64, 2016, LB505.